IP Library › Granted Patent US 11,590,128
Granted Patent B2
US 11,590,128 · App. 17/834,709 · Granted Feb 28, 2023

Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor

Inventors: Deepak Sampath (South San Francisco, CA); Christian Klein (Iffeldorf, DE); Wayne John Fairbrother (South San Francisco, CA); Sari L. Heitner Enschede (River Forest, IL); Rod A. Humerickhouse (Highland Park, IL); Andrew W. Roberts (Melbourne, AU); John F. Seymour (Melbourne, AU)
Assignees: GENENTECH, INC.; HOFFMANN-LA ROCHE INC.; ABBVIE INC.
A61K31/496A61K31/02A61K31/04A61K31/10A61K31/18A61K31/33A61K31/436A61K31/437A61K31/4375A61K31/45A61K31/505A61K31/63A61K39/39558A61K2039/545A61K2039/585
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,590,128
App. No.
17/834,709
Granted
Feb 28, 2023
Kind
B2
Abstract

The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.

Claims (7)

1. A method for treating acute myeloid leukemia (AML) in a human patient, the method comprising orally administering once daily GDC-0199 to the patient in escalating doses, wherein the escalating doses comprise an initial dose of 100 mg of GDC-0199 per day.

2. The method of claim 1 , wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab.

3. The method of claim 2 , wherein the effective amount of the obinutuzumab is 1000 mg.

4. The method of claim 1 , wherein the escalating doses further comprise a final dose of 400 mg of GDC-0199 per day.

5. A method for treating acute myeloid leukemia (AML) in a human patient, the method comprising orally administering once daily GDC-0199 to the patient in escalating doses, wherein the escalating doses comprise a final dose of 400 mg of GDC-0199 per day.

6. The method of claim 5 , wherein the GDC-0199 is administered in combination with an effective amount of obinutuzumab.

7. The method of claim 6 , wherein the effective amount of the obinutuzumab is 1000 mg.